Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

99.35EUR
3:26pm IST
Change (% chg)

€2.25 (+2.32%)
Prev Close
€97.10
Open
€97.95
Day's High
€100.10
Day's Low
€97.75
Volume
68,647
Avg. Vol
114,436
52-wk High
€100.10
52-wk Low
€55.05

Summary

Name Age Since Current Position

Marc Cluzel

58 2018 Chairman of the Supervisory Board

Simon Moroney

1998 Member of the Management Board, Chief Executive Officer

Frank Morich

2018 Vice Chairman of the Supervisory Board

Jens Holstein

2011 Chief Financial Officer, Member of the Management Board

Markus Enzelberger

2017 Chief Scientific Officer, Member of the Management Board

Anke Linnartz

2016 Vice President and Head of Corporate Communications and Investor Relations

Malte Peters

2017 Chief Development Officer , Member of the Management Board

Michael Brosnan

62 2018 Member of the Supervisory Board

Karin Eastham

67 2012 Member of the Supervisory Board

George Golumbeski

60 2018 Member of the Supervisory Board

Wendy Johnson

2015 Member of the Supervisory Board

Biographies

Name Description

Marc Cluzel

Dr. Marc Cluzel, M.D., Ph.D., has been Chairman of the Supervisory Board of MorphoSys AG since May 17, 2018. He was Member of the Supervisory Board at Morphosys AG from May 31, 2012. He has more than 20 years of knowledge and experience in Research & Development and product registration in the United States, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice President of Product Development at HUYA Bioscience International, LLC. Dr. Cluzel served as global head of Research and Development for Sanofi from 2007 to 2011, as Executive Vice President of Research and Development for Sanofi (Formerly Sanofi-Aventis SA) and before 2009 as its Senior Vice President of Science and Medical Affairs. He was also since 2002 Chairman and Chief Executive Officer of Sanofi-Synthelabo R&D France then Sanofi-Aventis R&D France. His career began in hospital medical care and gradually transitioned to research at Johns Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel holds both an MD degree and a Ph.D. degree from the Universite de Montpellier, France.

Simon Moroney

Dr. Simon E. Moroney is Chief Executive Officer and Member of the Management Board of Morphosys AG since 1998. He is responsible for the AbD Serotec business segment, business development, corporate communications and investor relations, human resources, strategy and planning, and the coordination of the Management Board reporting to the Supervisory Board. Prior to co-founding MorphoSys AG, between 1991 and 1992, Mr. Moroney held positions in the Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom. From 1989 to 1990, he served as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada. Before that, he worked as Associate in the Chemistry Department of the Eidgenoessische Technische Hochschule (ETH), in Zurich, Switzerland, from 1986 to 1989, where he also held the position of Lecturer between 1988 and 1989. From 1984 to 1986 he was an Associate in the Harvard Medical School, Boston, United States, and an employee of ImmunoGen Inc. He studied chemistry in New Zealand, and was a Commonwealth Scholar at the University of Oxford, where he completed a Doctorate in Philosophy in Chemistry in 1984.

Frank Morich

Dr. Frank Morich has been Vice Chairman of the Supervisory Board of MorphoSys AG since May 17, 2018. He was Member of the Supervisory Board at the Company from May 8, 2015.

Jens Holstein

Mr. Jens Holstein is Chief Financial Officer and Member of the Management Board at MorphoSys AG from May 1, 2011. He is responsible for accounting and controlling, corporate development, treasuryand technical operations including Information Technology (IT), and the corporate legal function. Prior to joining the Company he served as Regional CFO for Europe/Middle East and as Managing Director of Fresenius Kabi Deutschland GmbH. Over nearly 16 years at Fresenius Kabi Deutschland GmbH, he held a variety of financial and general management positions. Before that, he had spent several years in the consulting industry working in Frankfurt and London.

Markus Enzelberger

Dr. Markus Enzelberger is Chief Scientific Officer, Member of the Management Board of MorphoSys AG since November 1, 2017. He was Interim Chief Scientific Officer since April 15, 2017. He joined MorphoSys in 2002 and served in various leadership positions within the Company's R&D organization. Since 2012 he acted as Senior Vice President, Discovery, Alliances and Technologies, taking responsibility for the drug discovery activities for both MorphoSys's proprietary and partnered programs as well as for technology development.

Anke Linnartz

Ms. Anke Linnartz has joined as Vice President and Head of Corporate Communications and Investor Relations of MorphoSys AG effective November 1, 2016. Previously, she served at Gerresheimer AG, where she headed the Investor Relations und Creditor Relations department from 2008 to 2016. Prior to that, she was in charge of the capital markets communications at German M-DAX company Demag Cranes AG. Before that, she headed the capital markets communications of GEA Group AG, managing the communications of a transformative group restructuring process. From 1998 to 2004, she worked in leading positions for German business intelligence company MIS AG. Anke Linnartz was member of the Board of Directors of the German Investor Relations Association (DIRK) for nine years.

Malte Peters

Dr. Malte Peters is appointed as Chief Development Officer , Member of the Management Board of MorphoSys AG effectively from March 1, 2017. He served at Sandoz, where he serves as Global Head, Clinical Development Biopharmaceuticals. Dr. Peters built his career in early and late-stage clinical development over the last 18 years. Prior to his latest role at Sandoz, he spent 12 years in various managerial positions within Novartis focusing on management of clinical development projects in oncology. Before that, Dr. Peters served in positions as Medical Director at Micromet AG and as Head of Translational Research and Pharmacogenomics at Merck KGaA.

Michael Brosnan

Mr. Michael Brosnan has been appointed Member of the Supervisory Board of MorphoSys AG effective as of May 17, 2018. He has over 40 years of experience in finance, controlling and auditing. Since 2010, he has served as Chief Financial Officer of Fresenius Medical Care Management AG, Bad Homburg, Germany, a company with a dual listing in Germany (Frankfurt) and the United States (NYSE). Over the last 20 years, he has worked in various leadership and executive positions for Fresenius Medical Care in the United States and Germany. Prior to joining Fresenius Medical Care, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG. Mr. Brosnan holds a degree in business administration and accounting from Northeastern University, Boston, MA, USA.

Karin Eastham

Ms. Karin Eastham is Member of the Supervisory Board of Morphosys AG since May 31, 2012. She currently serves as Director on the Corporate Boards of Illumina, Inc., Amylin, Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer and as Member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc. and Cytel Corporation. She also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a Bachelor of Science degree and an MBA degree from Indiana University and is a Certified Public Accountant.

George Golumbeski

Dr. George S. Golumbeski, Ph.D., has been appointed Member of the Supervisory Board of MorphoSys AG effective as of May 17, 2018. He currently serves as Executive Vice President & Executive Advisor for Innovation at Celgene Corporation, Summit, NJ, USA. He will retire from this position on April 16, 2018. Over the last 27 years, he has held leadership roles in business and corporate development, partnering and M&A with global pharmaceutical and life science companies, including Celgene, Novartis, Elan Corporation (currently: Perrigo), and Schwarz Pharma (currently: UCB). Dr. Golumbeski obtained his doctorate in genetics from the University of Wisconsin in Madison, USA and holds a degree in biology from the University of Virginia, Charlottesville, USA.

Wendy Johnson

Basic Compensation